LearnGlossaryMarketStocksSuperinvestorsSign in

ADAG

Adagene Inc.

Healthcare · $120M market cap

Verdict

We can't put a fair value on ADAG right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-29.1% a year✗
Sales growth29.7% a year✓
Free cash flow growth—?
Return on invested capital-37.9%✗

Follow ADAG

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 16, 2026: 1 open-market purchase worth $64K. Why purchases matter

Purchases

Luo Peter

Chief Executive Officer · 2026-09-16

Bought

$64K

About Adagene Inc.

Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works